Biogen Inc. (BIIB) Earnings Call Transcript & Summary
July 25, 2023
Earnings Call Speaker Segments
Chuck Triano
executiveThanks, operator. Good morning, and welcome to Biogen's Q2 2023 earnings call. Before we get started, I'd ask everyone to visit the Investors section on biogen.com, where you can locate the earnings release along with the related financial tables — that includes our GAAP financial measures and a reconciliation between the GAAP and non-GAAP financial measures we'll be talking about today. Tables 1 and 2 contain our GAAP financials, and table 4 has a reconciliation of our GAAP to non-GAAP financial results. In our view, non-GAAP financial results give a better picture of the ongoing economics of our business and show how we manage things internally; we've also put slides on our website that will accompany the discussion on this call. I want to note that we'll be making forward-looking statements, which rest on our expectations; such statements carry certain risks and uncertainties, and our actual results could differ materially. For more detail, I'd encourage you to review the risk factors covered in our SEC filings. Joining me today are our President and Chief Executive Officer, Chris Viehbacher; Dr. Priya Singhal, Head of Development; and our CFO, Mike McDonnell. Each of Chris, Priya, and Mike will offer some opening remarks, after which we'll go to the Q&A session. So that we can get through as many questions as possible, we kindly ask you to limit yourself to one question. I'll now hand the call over to Chris.
Christopher Viehbacher
executiveThank you, Chuck. Good morning, everyone. I want to begin by discussing LEQEMBI. Before diving into all the fascinating specifics around commercialization and competition, I'd just like to take a brief moment; what we're witnessing is a landmark event in the history of healthcare. We're discussing the very first disease-modifying therapy that has been granted full approval by the FDA and secured reimbursement from CMS. And literally dozens of medicines had failed prior to this drug reaching the market. That matters for a few reasons — first, there's a tremendous amount we still don't understand. We truly are at the outset of a journey toward genuinely comprehending Alzheimer's disease and how we can influence it. But it's also going to significantly affect how medicine is practiced. Physicians haven't been able to do much for patients beyond maybe prescribing Donepezil or similar products. And the therapy we're putting forward here is genuinely going to transform a great deal about how doctors practice and treat these patients; so when we begin considering intent to prescribe and how physicians view things, we actually won't know that until we get out into the marketplace and observe how patients respond. ADUHELM did receive approval. But as all of you are aware, it never truly got off the ground, and never truly launched. So this genuinely is a first. And whenever you're first, you're going to be learning an enormous amount, and much of this simply isn't all that predictable. I would, once again, just offer kudos to our colleagues at Eisai. In a very brief span, they managed to submit regulatory filings in the EU, Japan, China, Canada, Great Britain, and South Korea; so this will be a genuinely global launch. Now, we just held the AAIC last week, and Priya will go over a bit more about that. But one thing that has become clear is when we begin examining Donanemab and Lecanemab, these are two markedly different products. And I don't believe most people have truly examined that. Most people are looking at it as, okay, we have an A-beta antibody and we're clearing plaques, but there's far more to this story, and it's going to unfold over the coming months and years. These are distinct products. They possess different mechanisms because they have different binding. They've been studied in different populations. They've been studied using different clinical study design process — design approaches; and naturally they have a very different safety profile. And all of these distinctions are going to manifest in the marketplace over the months and years ahead. It's going to be fascinating to watch how this plays out, but let me give everyone a word of caution: as this unfolds and you start seeing all the data, there's a great deal of nuance involved, and from a commercial standpoint it's going to be quite compelling. The US launch is now in progress; full approval came through earlier this month, and the CMS approval matters not just for us but for others too — it's going to spur many other companies to put money and research into blood diagnostics. As you're aware, this will also be an atypical launch. A tremendous amount of work lies ahead. Patient navigators will be in place to help guide people through the process, to understand how treatment will happen, and to secure reimbursement; we'll be collaborating with physician offices as well. A great deal of change will need to take place in practice — new practices, day in and day out. There's a tremendous amount of education needed around safety and making certain the right patients are identified. To date, we've contacted roughly 700 centers. Reimbursement is also coming in beyond CMS. Medicaid, for instance, is on board in 48 of the 50 states so far, and the response from commercial insurers has been very positive. So I'd say the LEQEMBI launch is off to a strong start, and naturally we'll keep you informed as more patients come through. Now let's turn to another slide. One thing we've been focused on heavily over recent months is making certain we're properly positioned for growth; and when we examined the company, this is where we stood. As you know, our product profile today is fairly mature. Typically, with a mature product profile, you'd anticipate investment levels declining. Yet our operating expenses are actually relatively high when measured against other companies. Part of the reason is over-investment in legacy products. On top of that, our governance is extremely centralized. We have numerous organizational layers. Our span of control is low; on average, it sits at three. Then, looking at the R&D pipeline, we've gone through five different R&D heads over 10 years, which isn't healthy for an R&D organization; consequently, we wound up with some products that I'd characterize as relatively high-risk and high-cost, and not necessarily the most valuable. So we've undertaken an extensive effort to thoroughly review those R&D programs. And when we considered where we want to be, well, we want to make more value-based decisions regarding existing products. We don't want to simply eliminate promotional effort altogether. In multiple sclerosis, Biogen continues to hold 25% of the market; no one else comes close to our share, which means a tremendous number of patients rely on what Biogen makes. My belief is that we can handle this more intelligently. Clearly, strong funding behind our new product launches is necessary. Keeping costs in check matters, of course, but shareholder value is maximized best when those launches genuinely succeed. Decision-making ought to sit nearer to the customers, the organization needs more agility, and R&D should concentrate on high-value projects. Through external growth, we'll gain a real chance to diversify beyond rare diseases — moving into rare diseases, immunology, and neuropsychiatry. That's why we undertook this redesign effort. Ours was a bottom-up exercise examining where the company must stand to launch new products successfully. Which internal governance mechanisms suit us? Which metrics? What form of accountability? So Biogen has undergone, I'd call it, a thorough redesign, and cost savings will follow from it. Gross savings will come to roughly $1 billion in annualized savings each year. Out of that, we intend to put at least $300 million into growth opportunities moving forward. This gives us a chance to ensure that this year, prior to reaching the product launches, we were genuinely fit for growth. With that, I'll hand things over to Priya.
Priya Singhal
executiveThank you, Chris. It's our view that the standard approval granted to LEQEMBI marks a major step forward for the Alzheimer's field. At the same time, we acknowledge that finding therapies that truly work against Alzheimer's remains an ongoing effort. Biogen and Eisai keep producing data on LEQEMBI throughout the Alzheimer's disease continuum. Amyloid pathology may show up years prior to symptoms appearing. Treating at an earlier stage — to delay or perhaps even stop Alzheimer's from developing — could potentially maximize LEQEMBI's therapeutic effect. To test this strategy, Eisai and Biogen launched the AHEAD 3 to 45 trial back in 2020; it's made up of two sister trials involving cognitively unimpaired people between the ages of 55 and 80 who showed intermediate or elevated amyloid levels on PET screening, and these participants will be assessed across 48 months. Following LEQEMBI's US approval, we also changed the protocol for the AHEAD trial so that open-label LEQEMBI rescue becomes available if patients progress to early AD during their participation in the trial; our view is that LEQEMBI's clinical profile is uniquely well suited to the early intervention strategy, given robust plaque clearance, a low incidence of ARIA, and the option of longer-duration treatment that could potentially maximize clinical benefit. We're focused on improving and simplifying the patient journey for LEQEMBI in early AD. Our efforts center on two areas: a subcutaneous formulation, where an auto-injector that could potentially allow at-home administration is in progress. At AAIC, Eisai recently shared modeling data indicating that subcutaneous lecanemab delivers similar exposure and amyloid plaque reduction compared with the bi-weekly IV formulation, yet with the potential for a lower incidence of ARIA. A regulatory filing is anticipated by the close of Q1 2024. The second area is maintenance dosing. Less-frequent maintenance dosing is being evaluated in the Phase 2 open-label extension. A regulatory filing is likewise anticipated by the close of Q1 2024. We're also still analyzing the Clarity AD data, where we've seen consistent reductions in both amyloid and tau PET along with improved clinical outcomes, as our goal is to better inform treatment decisions for patients. The Clarity AD study didn't rely on baseline tau PET as an exclusion criteria and enrolled a broad early AD population whose tau pathology at baseline varied in degree. This key feature of the Clarity AD study made it possible to generate data on individuals with low tau burdens — something no other Phase 3 programs have collected. At AAIC, Eisai shared baseline characteristics along with a new analysis featuring the initial results from Clarity AD's tau PET sub-study. In that analysis, people enrolled in the tau PET sub-study were sorted into high, medium, and low groups according to tau burden measured at baseline. Lecanemab administration demonstrated a clinical effect across the overall population of the tau PET sub-study, and notably, a large effect size was also seen in the low tau population as defined in this analysis, which does represent the early phase of AD. It's our belief that these data lend further support to the clinical benefit observed with LEQEMBI in the broad early AD population. Once more, this underscores how crucial it is to treat patients at an early stage. At Biogen, we intend to extend our leading industry position in therapies aimed at A beta clearance and tau knockdowns by moving forward a portfolio spanning multiple targets and modalities, which also includes additional emerging targets within the Alzheimer's disease pathway; that covers programs directed at tau. BIIB080, an antisense oligonucleotide in Phase 2, and BIIB113, a small molecule in Phase 1 designed to stop tau activation. Turning to SMA, interim findings from the response study were shared at the Cure SMA Conference not long ago and show that the majority of participants, one investigator, and caregivers described sub-optimal clinical status across several domains at baseline, after receiving zolgensma treatment; this covered motor function, the ability to swallow or feed, and respiratory function. We think this could stem from slightly incomplete transduction of motor neurons after gene therapy was given. The internal results at six months reveal gains in motor function for most participants, as measured by a higher total HINE-2 score compared with baseline, with no new safety concerns emerging. On the whole, we think these findings hint that extra benefit may be possible from SPINRAZA treatment after zolgensma has been administered. As Chris noted, the R&D organization has devoted considerable time and effort over the past several months to a thorough review of Biogen's R&D programs, since we want to enhance the pipeline's risk profile and productivity. We reached a number of major decisions and pinpointed the programs we wish to prioritize. As for others, where we judged that the difficulties led to a low probability-adjusted return on investment, they were quickly altered or halted. We believe this has produced a leaner pipeline with a generally higher chance of success and a tighter focus on key programs. Every example listed here has data readouts anticipated within the coming years. BIIB080, a Phase 2 ASO aimed at tau, which has 1b — Phase 1b data demonstrating a time- and dose-dependent decrease in CSF total tau and phospho-tau, plus tau tangle seen through tau PET. Litifilimab, a subcutaneous anti-BDCA2 antibody, now under evaluation in two Phase 3 trials for systemic lupus erythematosus and a Phase 2/3 trial for cutaneous lupus erythematosus. BIIB105, an ATXN2 ASO under evaluation in a Phase 1/2 trial for broad sporadic ALS, with a readout expected mid-year 2024. BIIB122, a LRRK2 ASO being developed alongside Denali Therapeutics, presently in a Phase 2b trial for idiopathic Parkinson's disease; and BIIB121, an ASO intended to boost expression of paternal UBE3A in Angelman syndrome, and we anticipate the Phase 1 readout at mid-year 2024. To sum up, during the past quarter we kept achieving substantial progress throughout our pipeline, especially with the traditional approval of LEQEMBI in early AD. Although our initial substantial review of the pipeline has finished, we will keep assessing both existing and possible new R&D programs through a data-driven approach, with close attention to risk balance and value creation. I'll now hand the call to Mike.
Michael McDonnell
executiveThanks, Priya, and good morning to all of you. I'll share a few highlights and some context on how we performed financially in the second quarter, and every comparison I make is against the second quarter of 2022. Consolidated revenue came in at $2.5 billion for Q2, which represents a 5% decline on a reported basis and 3% in constant currency. Non-GAAP diluted EPS for the quarter was $4.02. Revenue from our MS Products totaled $1.2 billion, down 15% as reported and 14% in constant currency. Now, a handful of recent developments in the MS business during this quarter. To begin with, the drop in MS during Q2 stemmed from generic competition for TECFIDERA as well as wider competitive pressure across the MS category. Channel dynamics were not a significant factor in the second quarter. Next, as we shared earlier, TECFIDERA's regulatory market protection in the EU gained an extra year, now running until February 2nd of 2025. A number of TECFIDERA generics have still not completely left certain EU markets, and some generic products are still sitting in the channel. Generic withdrawal has moved more slowly than we anticipated, and we are keeping a close watch on the situation while working to uphold our legal right-to-market protection. Turning to TYSABRI, we've said before that a TYSABRI biosimilar could launch in the US and EU at some point later in 2023. We're aware of the positive CHMP opinion last week for the TYSABRI biosimilar in the EU. And although no biosimilar launches have occurred yet, an approval and launch could come in the months ahead. Now let me move to SMA. SPINRAZA revenue worldwide reached $437 million, up 1% as reported and 5% in constant currency. In the US, SPINRAZA grew 12%, driven by an increasing number of patients. We felt good about how the business did this past quarter and think we're making solid headway toward our objective of getting SPINRAZA back to consistent growth; in addition, as Priya noted, we keep generating data to bolster SPINRAZA's efficacy profile. And we think this, together with the overall market expansion we expect, should help support continued better results for SPINRAZA. Biosimilars brought in $195 million, flat as reported and up 4% in constant currency. We continue to handle supply constraints affecting IMRALDI and BENEPALI, and we're watching that situation very carefully. As we've said before, we're assessing whether this business might deliver more value outside of Biogen, and we're in discussions with several interested parties; we'll give further updates on that process when it's appropriate. Alzheimer's disease revenue, which covers ADUHELM plus the LEQEMBI collaboration, amounted to a $20 million drag on revenue in the second quarter. As a reminder, LEQEMBI revenue reflects our 50% share of end-market revenue minus 50% of commercialization expenses. For 2023, we anticipate that this line will stay negative, since costs tied to ramping up LEQEMBI commercialization are going to outpace the revenue we bring in early on. Anti-CD20 revenue came to $433 million in total, a decline of 1%, and that figure included a $12 million operating loss tied to LUNSUMIO. Just a reminder that beginning with this quarter, our pre-tax share of profits on RITUXAN, GAZYVA, and LUNSUMIO moved down to 35% from 37.5%. The reason is that certain sales targets for GAZYVA have been met under the contractual arrangement we have with Genentech. Contract manufacturing, royalty, and other revenue reached $198 million, which was notably higher versus the prior year, mainly because of batch timing. A few points on Q2 expenses. Non-GAAP cost of sales for the second quarter came in at 24% of total revenue, which includes $34 million of idle capacity charges. We keep seeing a higher cost of sales as a percentage of revenue, driven by product mix and idle capacity charges, and specifically, the growth we're experiencing in contract manufacturing revenue pushes up our overall cost of sales as a percentage of revenue. So when modeling the rest of 2023, I'd suggest that we think contract manufacturing revenue will stay strong and will lead to a higher cost of sales as a percentage of revenue for the balance of this year relative to the 24.1% recorded in the second quarter. Second quarter non-GAAP R&D expense includes approximately $13 million in estimated study closeout costs tied to BIIB093. As Priya noted, our R&D prioritization is now substantially complete; we estimate gross savings of roughly $250 million next year will result. Natural increases in R&D from portfolio progression will partially offset that. The lower second quarter SG&A expense stemmed from about $70 million of savings initiatives, partly offset by roughly $35 million of reinvestments, mostly for launch costs. We still expect operating expenses in the second half of the year to be below the first half, as we finish capturing the run-rate savings from cost initiatives we previously announced, along with a modest effect from our new fit-for-growth initiative. So let me now spend a minute giving a bit more detail about our new fit-for-growth program. This program involves changes to our operating model, including a significant reduction of certain centralized functions. A substantial portion of the $700 million in net annual OpEx savings is expected to come from a net reduction in headcount of approximately 1,000, which we expect will right-size the company in line with our business plan and allow us to return to sustainable growth. I'd like to reiterate that the OpEx savings shown here are on an annualized basis. We believe this is an efficient program, with 70% of our expected gross OpEx savings to be realized as net savings. Taken together, we anticipate only a slight effect on expenses for 2023, and we think the net OpEx savings will be divided about evenly across 2024 and 2025. Also, every one of those savings comes on top of any cost-cutting initiatives we had already announced. A handful of brief remarks about our balance sheet, among them the roughly $813 million we brought in during the quarter from selling our equity stake in Samsung Bioepis. We closed out the quarter holding $7.3 billion in cash and marketable securities. As of June 30th, our debt stood at $6.3 billion, which leaves us in a net cash position of approximately $1 billion; we keep producing consistent, positive cash flow from operations, with free cash flow of $416 million in the second quarter; and lastly, let me now move to our financial guidance for the full year 2023. The business is still tracking with what we projected for the entire year; and as of today, we are restating our full-year guidance of a 2023 revenue decline in the mid-single-digit percentage range relative to 2022 reported results, along with full-year 2023 non-GAAP diluted earnings per share between $15 and $16. And for additional key guidance assumptions, you can look at our press release. So with that, I'll hand things back to Chris for some closing remarks.
Christopher Viehbacher
executiveI appreciate that, Mike. So beyond restructuring what it costs us to operate, we are likewise reshaping the commercial lineup we bring to market. Two green lights have come our way already during this year: QALSODY and LEQEMBI, both here in the United States. Looking ahead to what remains of this year and the start of the next one, several significant portfolio milestones lie in front of us. A verdict from the PMDA in Japan should arrive during the third quarter. From the EMA across Europe, we anticipate one in the first quarter of next year. China is also expected to weigh in during the first quarter of next year. On top of that, a decision from the FDA regarding zuranolone could come as soon as next week. And we keep advancing LEQEMBI as well. Per what Priya mentioned, we anticipate filing the regulatory dossiers for LEQEMBI subcu during Q1 of next year, along with a regulatory submission for maintenance dosing at some point next year. Beyond all of that, given the forthcoming approvals of new products, we will of course keep examining possibilities for growth from outside the company. As I've noted previously, here lies a chance to broaden the portfolio further into rare diseases, immunology, and neuropsychiatry. With that said, Chuck, I'll hand it back to you to open things up for questions.
Chuck Triano
executiveThanks, Chris. Operator, can we please poll for questions?
Brian Abrahams
analystHi there, and good morning everyone. I really appreciate you giving me the chance to ask something, and congratulations on everything you've been accomplishing. So a competitor recently presented some data at a medical conference. And what I'm wondering is, now that you've watched this area develop, what would you say are the biggest takeaways regarding the efficacy and safety profiles across the whole beta-amyloid category? And could you perhaps go into a bit more depth about your current thinking on how competition in this space will shake out, plus what that means for your launch strategy overall? Thank you.
Christopher Viehbacher
executiveAppreciate that question, Brian. From a commercial standpoint, this is going to be extremely fascinating. That's because so many distinct elements are in play here. As I mentioned, I believe, the way the markets tend to frame it is that you've got two A beta antibodies, they clear plaque, and that's the whole story. In reality, the picture is far more complicated than that. To begin with, what I'd point out is that these two products — they actually attack the problem through different mechanisms. And among the most compelling findings likely to emerge from all this are the soluble protofibrils. Of all the forms of A beta, these are the most neurotoxic. Now, Lecanemab targets them, while Donanemab does not. And we're talking about the soluble forms here. In our view, that's genuinely going to matter, because we see this as more of a chronic condition — you're able to clear the plaque, yet these soluble forms, as judged by what some of the biomarkers are showing us, might well keep playing a part, and that's exactly why we believe a maintenance therapy will be needed down the road. Beyond that, the way these patients were studied also differs. For one thing, the patient populations were quite distinct from each other. Lecanemab, in fact, was studied in a population at an earlier stage — approximately two-thirds had MCI while one-third had mild disease, and with Donanemab that ratio was flipped. That matters a great deal, since progression rates vary among these patients. So actually, when Priya brought up those low tau patients, who have no overlap with the low tau — the low-to medium tau that Donanemab looked at, these are people whose disease would progress really quite slowly. So being able to observe an effect of that kind, I think, truly highlights how efficacious this product is. On top of that, you've got all the varying endpoints. Lilly's primary endpoint was one that Lilly itself designed. For Lecanemab, the gold standard was used, meaning the CDR sum of boxes. Yet once you begin examining activities of daily life, differences start emerging, and there are additional markers where we believe we can show where the efficacy lies. And naturally, safety is going to loom large. For most neurologists — if ARIA is something they've encountered previously, that's been fairly uncommon. I mean, we're aware ARIA can show up even among those on placebo, but it isn't something they'll have come across frequently. So for them, this will be a new experience, first of all — having to consider safety monitoring through MRIs. Still, sitting at a conference and reviewing safety as a data point is one thing. Actually looking at MRIs and witnessing ARIA, I'd say, is quite another. And I believe lecanemab's safety advantage is going to matter considerably to physicians going forward. So here we have multiple dimensions that I expect will unfold with time. You'll also have all the various blood diagnostics entering the picture. My own personal view is that, as the years pass, we'll see treatment happening progressively earlier, before neuronal death has gone too far. And naturally, that's precisely where LEQEMBI's benefit will come through, since they've already studied far more of these patients. Broadly speaking, what I'd say is that Lilly has concentrated on examining subpopulations, trying to make the case that, okay, within this subpopulation we achieved this result, and within that subpopulation another result. But when physicians are treating patients in their practice, subpopulations aren't what they want to grapple with. What they want is a medicine offering genuinely broad coverage. And that, I think, is another place where LEQEMBI will show what it can do. So this will be quite fascinating. There's a wealth of data that's come out of the AIC to sift through, and much of it will simply become far more concrete in the months and years ahead.
Chuck Triano
executiveThanks, Chris. All right, can we poll for next question, please?
Marc Goodman
analystYes, good morning. Mike, I just want to confirm we're on the same page regarding the cost savings figures. So operating expenses, $4.5 billion for 2023. That means we should be anticipating $3.8 billion in 2025. And then, how do we arrive at that in terms of SG&A and R&D? Are these roughly equal? I mean, will R&D drop under the $2 billion threshold? Could you just give us some clarity on that? And perhaps while you're discussing the P&L, could you also mention whether you anticipate gross margins being greater or smaller during those years, just to assist us in understanding what the P&L will resemble. Thanks.
Michael McDonnell
executiveYeah. Mark, I appreciate the question. So, your calculation is right. Our aim is to reach a complete run rate of the $700 million in net savings by 2025. So with an operating expense base of $4.5 billion, that would bring it to approximately $3.8 billion. The savings are going to come from both SG&A and R&D. We've already accomplished a considerable amount in R&D, as we mentioned, and that will produce substantial savings through our prioritization program. But we'll also be exploring methods to run our clinical trials, our current trials, more efficiently. So the total savings will be a combination. We aren't giving complete detail on whether R&D will be above or below the $2 billion figure you mentioned; however, I'd guess that the savings going forward would likely lean somewhat more toward the SG&A line and somewhat less toward R&D. But in the end, the savings will come from both areas. The gross margin, that's a pattern we anticipate will persist at least in the short term. And when you examine the product mix, we clearly have ongoing decreases in certain MS Products, which are on the higher-margin side, and then you have contract manufacturing that's actually expanding quite a bit compared to the prior year; so we do expect our cost-of-sales as a percentage of revenue, at least in the near term, to be somewhat lower than what we've heard — or rather, the cost-of-sales percentage would be higher, the gross margin would be lower than what we've experienced previously. And then eventually, as LEQEMBI turns profitable and scales up, we should ideally see some improvement on the gross margin line.
Chuck Triano
executiveThanks, Mike. Can we go to our next question, please?
Robyn Karnauskas
analystHi there, and thank you for letting me ask. I suppose what I'd be curious about right off the bat is whether, when you speak with physicians, you see any gap between the academic world and the community setting — both in their appetite for prescribing the drug and in how they coordinate that. Could you share more about how laborious versus how straightforward the CMS registry is now that it's live and running? Are there additional questions coming from them? Thanks.
Christopher Viehbacher
executiveOn the registry, I'd say first that everything we're hearing back is that it's manageable. Ideally, nobody would want a registry at all, but having gone through it myself, you've got dropdown menus, and the bulk of the data can be pulled from medical records, so that piece, we believe, should be fine. There's a bit of turbulence regarding reimbursement for the PET scan, and that ought to get sorted out within the next 90 days. Still, as things stand today, the single PET scan that's covered shouldn't stand in the way. Really, it comes down to the logistics — I've watched patients who will switch. You're going to need to perform more cognitive testing, secure the PET scanner, arrange the lumbar puncture, work out where to send people for MRI infusion centers, and then obtain the three MRIs. Offices will eventually settle into a routine, but at the outset, virtually no one is doing this yet. Naturally, a handful of centers managed to begin infusing LEQEMBI in the window prior to traditional approval; however, looking at the broader population, everyone has to ramp up for this. Another point I'd make is that this field has seen an enormous amount of disappointment through the years. There was plenty of hope, yet many of these medicines never panned out; as a result, a great deal of wait-and-see has existed among portions of the medical community. Will we truly secure full approval? Will we truly secure CMS approval? So now that it's in place — which, as I've mentioned previously, I regard as a genuinely seminal moment in healthcare — we'll witness how the practicalities unfold. And we've consistently stated that revenue uptake here is going to be relatively measured. That said, our entire field organization is geared up for this. This field organization is far more complex than what a typical launch would involve, with the care navigators, with MSOs, with field reps, with regional thought leaders, professionals. So a great many people will literally be holding hands with patients, with physician practices, working to help ensure this goes as seamlessly as possible; and yet it clearly isn't as simple as writing a prescription for a pill and heading to your neighborhood pharmacy.
Chuck Triano
executiveAppreciate it, Chris. Operator, could we get the following question, please?
Mohit Bansal
analystWonderful. We really appreciate you fielding this. This one might be for Priya. When it comes to subcutaneous LEQEMBI, and the data will arrive later in the year, how are you viewing its positioning? Would you frame it more as a maintenance option following IV LEQEMBI, or as something along the lines of an induction therapy? Also, how crucial is Cmax when it comes to securing an induction approval in this case? That's extremely useful. Many thanks.
Priya Singhal
executiveMany thanks, Mohit. That's an excellent question. Perhaps, prior to responding to it, let me note that both Biogen and Eisai genuinely aim to streamline and enhance the patient journey, and that involves multiple approaches. The first is a subcutaneous version, capable of solving infusion capacity constraints and other problems, plus the possibility of an auto-injector and at-home self-administration. The second involves genuinely considering how LEQEMBI might be positioned to tackle the long-term duration issue that remains unresolved. What's encouraging is that LEQEMBI does present the chance to be used across a lengthy duration. The real issue is: what maintenance duration is appropriate for this therapy? As for subcutaneous, the data we recently shared at AAIC consisted of modeling data indicating that the subcutaneous version would involve roughly 720 milligrams given once per week, rather than the intravenous therapy taken every two weeks. What matters most to grasp here is that the hope, and the data, suggest safety might in fact improve with the subcutaneous version; thus, we could see reduced ARIA rates. The filing should be finished by Q1 2024. I also anticipate that additional data — Eisai has said as much — will come out at CTAD this year. So let's hold off for more of that data, which I believe is on its way; and we're eager for the — ideally — simplification of the patient journey.
Chuck Triano
executiveAppreciate that, Priya. Let's move on to the next question.
Umer Raffat
analystHey, everyone. Thanks for letting me ask. There's clearly something nobody's addressing, and honestly it deserves discussion; and Chris, I'm directing this at you in particular. What people want to know is this: what went through your mind at two particular moments over these past few weeks? One, when the proposed Board changes first came to your attention, what did you think? And two, how did you reason through whether any disclosures were necessary?
Christopher Viehbacher
executiveIf we take a step back, obviously plenty of folks zeroed in on certain rumors; but at a more basic level, our Board has undergone a major shift. And anyone familiar with how Boards operate knows that major Board changes only happen when the Board reaches consensus. A Board functions as a group of equals holding the same authority. There had also been considerable engagement from investors. Internally, this company is implementing a great deal of change at the management layer, tackling many of the issues that investors, in my view, have been voicing over many years and certainly issues that have reached my ears; and the Board itself concluded, well, we ought to examine our governance and ask whether we too are evolving; and I can tell you that every discussion I took part in centered on a single consideration, namely, what serves Biogen best; and I found that quite heartening. That said, we have a new chair and honestly I could not be more pleased to work alongside Caroline. She possesses integrity beyond reproach, is remarkably intelligent, thinks analytically, yet genuinely cares deeply about this company's mission. And in my view the Board stands fully behind every change we are undertaking; so all of that strikes me as positive. Regarding disclosure, our focus is on individuals; personal relationships are not what we examine. I would simply note that Glass Lewis and ISS both backed Susan Langer, and investors elected her to the Board, and I don't believe anything further needs to be — anything more requires saying on that matter.
Chuck Triano
executiveThank you, Chris. Can we move to our next question, please?
Salveen Richter
analystThanks, and good morning. In what ways did the fit-for-growth initiative and your efforts around cost alignment shape how you're thinking about M&A and BD? You mentioned the three disease areas — could you share some perspective on what the value proposition looks like in each of them? Are there any constraints when it comes to deal size or the use of equity? Thank you.
Christopher Viehbacher
executiveKeep in mind that fit-for-growth really mirrors where the company is heading. For more than 45 years, multiple sclerosis has been our central focus. During the more recent chapter of our history, we enjoyed some quite successful periods. And now that fortunes have shifted for a number of those products, I believe that, as an organization, we hadn't truly implemented the adjustments to our organizational structure and our cost base needed to mirror that transition. Something I like to share with our management teams is that and is the most difficult word in management. You must consider both the near term and the far term. Yet one key point is that you need to keep costs lean and simultaneously put money into growth. That has proven to be a quite delicate balancing act. Were it not for all the product launches, cutting costs alone would be relatively straightforward. What we've needed to do is think far more carefully about the optimal approach to positioning Biogen going forward. That's the reason we didn't begin from our current position, but instead began from our desired destination. What should that organization look like? What headcount? We did benchmarking against peers. We've examined the — ensuring we have sufficient funding for the product launches, sufficient funding for those compelling R&D projects we'd want to prioritize, and then reasoned backward from that point. So I believe the company is now well situated to be geared toward growth while still overseeing our legacy portfolio. And once more, I'll reiterate that we remain the market leader in MS, and we owe something to both physicians and their patients in that regard. And so we will be altering how we — the promotional mix, but we won't simply abandon that either. And regarding M&A and external growth, the real question is what do we do to build upon that? That begins with BD at an earlier point in the pipeline. Are there things we'd like to build on top of that? And specifically, as I've mentioned before, I think we take pride in our standing in neuroscience; however, neurological conditions are diseases that progress slowly and genuinely demand extremely costly, lengthy trials. And they're the kind where you can't truly reduce risk using a Phase 2 asset. So we have no intention of walking away whatsoever, but we do need to make portfolio decisions that let us get a clearer read on efficacy and safety during Phase 2. And I believe that's achievable in rare diseases, where we'd lean more heavily toward immunology. Immunology has, after all, never been distant from this company throughout its history. Naturally, with — we're already present in neuropsychiatry, and the question is whether we can grow that portfolio. That said, I think what we have today is a far more agile structure and an organization with greater empowerment. A finding from our culture surveys is that reaching a decision can take us a very long time. So across all of that, when working with partners and pursuing business development, if nimbleness and the capacity to be agile are what you're after, then fit-for-growth should genuinely help enable it; though in truth, our approach to growth from outside is more strategic in terms of how we shape the company's portfolio.
Chuck Triano
executiveSo that also constrains how much equity can be used and what it's for. That's one piece of what you're asking, Chris.
Christopher Viehbacher
executiveMy view is that we need to focus on whatever truly benefits the company. Nothing has come up that I believe would necessitate issuing equity. Mike, if I recall correctly, we hold roughly $7.3 billion in cash. So from my standpoint, we don't — anything we're contemplating can be handled with the resources already on hand. The key priority is to really — a big part of what we're attempting through fit-for-growth is becoming far more disciplined regarding capital allocation; we've enjoyed tremendous luck across the past few years. And when a company is sitting on plenty of money, you tend to lose that discipline in how you deploy capital. That's a genuine priority for us; we truly want to ensure our investments go toward the areas delivering the strongest returns for the company and our shareholders. So that piece represents a cultural change emerging from this effort, and I believe it will shape our thinking around business development too.
Chuck Triano
executiveExcellent. Let's take the next one.
Michael Yee
analystHi, everyone. Thanks. I'd like to ask about the zuranolone program. Clearly, a PDUFA date is approaching; but Chris, in the past you've said some fairly optimistic things on this. Perhaps calibrate your expectations regarding how we should view that opportunity and whether a split label is possible? And crucially, given that you're discussing cost reductions, how might a favorable approval or perhaps some form of two separate indications affect expenses down the road? So please say a bit about zuranolone. Thanks.
Christopher Viehbacher
executiveYes. Well, our PDUFA date falls on August 5th; so once the FDA has decided, we'll be in a position to provide a complete update. So I'd rather not discuss that process at this moment. I'll simply say there's a tremendous unmet need in full health. And it appears only to be growing. You can't check the news without seeing stories about mental health conditions increasing. I believe the pandemic partly made that worse. And one of the things — that the pandemic accomplished was, I think, truly to bring this more into the open, where it ought to be. Without question, PPD is a tremendous unmet need, with a huge taboo surrounding it. And that will actually be a rather heavy lift, because there isn't really — there isn't really clarity regarding who is truly responsible for diagnosing and treating mothers at that stage. And so we look forward to being able, hopefully, to contribute to that. But there's also a considerable unmet need in how it's treated. I think something that — that might work much more quickly than treatments available now, something that's possibly episodic, could be extremely valuable to patients. So I do believe an opportunity exists. But once more, we must await the FDA decision, and we'll give everyone a full update at that time.
Chuck Triano
executiveThanks, Chris. Can we move to our next question, please?
Tim Anderson
analystThanks. Biogen and Eisai keep emphasizing that Alzheimer's therapies—particularly LEQEMBI—must be given on an ongoing basis rather than for a limited stretch. You also bring up protofibrils, calling them the most neurotoxic species, and so on. As I grasp it, the evidence supporting the idea that ongoing administration targeting less soluble A beta forms is necessary to meaningfully affect continued disease progression is quite weak. And when we simply examine the data presented at AAIC, we observe comparable reductions and cognitive gains from time-limited treatment with Donanemab, alongside ongoing curve divergence for Lilly's drug and for yours. So might that not cast doubt on whether ongoing dosing is actually required? And could that represent a danger for LEQEMBI—that physicians merely prescribe it until plaques are gone and then halt treatment, resulting in a substantially different revenue outlook for LEQEMBI? Thanks.
Christopher Viehbacher
executiveDr. Singhal?
Priya Singhal
executiveMuch appreciated for that inquiry. Indeed, this topic represents a crucial domain of investigation and scientific theory. Therefore, perhaps prior to diving into details about LEQEMBI or Donanemab, let's establish common ground that Alzheimer's disease is genuinely a worsening condition that ultimately proves lethal, with neurodegeneration clearly occurring throughout its course. What has been observed regarding LEQEMBI, and in fact through numerous sources of proof beyond LEQEMBI, including aducanumab previously, is that once plaque gets cleared, it doesn't build back up so readily. However, what becomes apparent is that the illness keeps advancing and there's an effect on fluid biomarkers. Consequently, regarding LEQEMBI and the interruption interval experienced during Phase 2, an elevation was observed — a reversal of the A beta 42:40 ratio, suggesting ongoing disease progression. Quite comparable proof emerged with aducanumab; and I believe what's evident today through plasma p-Tau measurements, previously, was that with aducanumab there was somewhat of a decline according to the EMERGE data set. As for LEQEMBI, what has been documented concerning p-Tau181 amounts to a stabilization. Furthermore, in the event you examined the Donanemab findings regarding p-217, the plasma tau biomarker those researchers employed, and these correspond quite tightly, is a modest rise. Thus, I believe additional data transparency remains necessary to grasp the Donanemab information about what truly occurs among patients who halted treatment at six months or halted treatment at one year. Our expectation is that additional information will emerge from their open-label extension, enabling us to reach conclusions. Yet whenever examining the substrate for Donanemab, persisting with dosing genuinely lacks justification. Firstly, owing to substrate exhaustion, and secondly, owing to the existence of antidrug antibodies, approximately 84% to 87%. Conversely, with LEQEMBI, there exists the possibility for a tailored treatment length conversation involving the patient and physician since, in fact, it keeps affecting soluble substrate, as Chris pointed out, and we intend to produce data examining this in a highly methodical manner through the Phase 1 open-label extension; therefore, I think the verdict remains uncertain, yet the numerous sources of proof appear not to suggest that Alzheimer's disease can be halted and reversed; so I'll conclude my response there. Thanks.
Chuck Triano
executiveThank you, Priya. Operator, let's take the next question.
Evan Seigerman
analystHey, everyone. I appreciate — I really appreciate you fitting my question in. Now that you've walked us through part of the right-sizing you intend to carry out and your attention has shifted toward BD in the second half of the year, could you share your thinking on what value remains available for BD in the current market? Also, are you zeroing in on nearer-term revenue chances to expand the business, or on development items at an earlier stage? Thanks.
Christopher Viehbacher
executiveHonestly, it's rather fascinating. Right now, when I speak with bankers, it's intriguing. My sense is that if you hold something with genuinely strong data, a price tends to exist for it, and that price stays roughly the same. I put a question to bankers: would Merck have needed to pay a larger sum for Prometheus, say, two or three — two years back, during what you could call biotech's boom period, and their answer is no. So I think when you locate quality assets, that part doesn't move very much. What does move is everything else, correct? There's somewhat more appetite for things that are more speculative, and that's really what determines whether things look comparatively pricey or not. As an organization, I've always enjoyed saying that our investors (Technical Difficulty) want them made wealthy, not the shareholders of some other company. Therefore, if a deal is going to happen, you must confirm there's value creation for Biogen and those holding its shares. That's a difficult task. And we're all aware that plenty of BD fails to achieve it. The way I see Biogen, we've got — there's now the LEQEMBI decision behind us. There's a pending FDA decision for zuranolone, plus pending LEQEMBI decisions globally. If you examine Biogen across the coming two or three years, a chance exists to return to growth during that period. I believe we're taking some audacious steps to tackle our cost base and genuinely reposition the company's resources. And we possess, I'd say, several tremendously compelling products within our R&D pipeline that Priya brought up; so when you consider it, a value-creation story is already in place. Consequently, whatever we pursue must be accretive to that picture; and you do need to search, and you'll need to examine a hundred things before locating one that truly works, which is precisely what our teams are up to. The most damaging move possible is to fall in love with something, since then you lose the — your objectivity slips away. Let me be clear that our top priority right now is turning around where our stock trades, since a great number of investors have told me that for a full 10 years, our share price has barely budged. That's the thing we're putting our energy behind — paying far more attention to value for shareholders, which means putting our capital to work in a manner that matches that goal.
Chuck Triano
executiveThanks for the views, Chris. Next question, please.
Ami Fadia
analystHello, and good morning. I appreciate you taking my question. This may follow up somewhat on what was just discussed. Given the fit-for-growth initiative, would it be fair to say that when it comes to BD, a deal bringing substantial R&D upside is probably not something you'd pursue across the coming 2 years? Also, could you share any detail regarding how you expect gross margin to move from 2023 through 2025? That would be useful. Thank you.
Christopher Viehbacher
executiveI didn't catch part of what you said about — does that mean, on the BD side, that we wouldn't do something, and I couldn't — I didn't. Would you mind repeating your question?
Ami Fadia
analystOkay, so does that mean you wouldn't sign off on a deal — right, that you wouldn't pursue something requiring a major R&D effort across the coming 2 years?
Christopher Viehbacher
executiveHonestly, I'd say there's already plenty of heavy lifting on the R&D side for us. So the way I look at it, what matters to me isn't so much the spending as the level of risk being taken on. What's difficult for me is a Phase 3 program stretching over multiple years, 5 years, that's basically serving as a proof-of-concept — that's the kind of thing I think we're genuinely trying to get away from. That said, what I'd add is that we're definitely doing benchmarking. And I truly want us to hold ourselves to a strict standard on G&A. I want us to be able to compete on sales and marketing. When it comes to R&D, I want us to be extremely disciplined about capital; still, based on all the benchmarking we've carried out, Biogen has in fact performed above average on productivity; and I have a lot of faith in the capabilities that exist within Biogen; so if opportunities genuinely make sense, my confidence in our R&D organization is actually quite high, and I believe we ought to keep putting money into R&D. What really matters is this — the hidden truth about R&D is that you need to design a killer experiment, set out clearly what the criteria are for advancing to the next stage, and refuse to commit capital unless those data are truly met. The trouble in many organizations is that we become infatuated with something. The data aren't entirely convincing, yet we push ahead and continue because it's already in our hands. And I'd argue the discipline to kill programs that miss their milestones probably matters more than anything else when it comes to managing R&D investments; that's exactly why I'm thankful to have Priya, since I think Priya is remarkably objective about this — as all of us are. But once again, I do believe we're an innovative company. And I wouldn't want to overly constrain Biogen's capacity to put money into R&D over time, though we will be incredibly demanding about what we decide to develop.
Michael McDonnell
executiveAlso, Ami, perhaps regarding the gross margin line and what sort of trajectory we should anticipate there. During our prepared remarks, we mentioned that throughout the remainder of 2023, we anticipate cost of sales as a proportion of revenue will keep climbing, and this is largely linked to the unusually large contract manufacturing revenue we are generating during this year. While I won’t provide guidance past 2023, looking at trends, if you consider a few of our larger ticket items, we have the anti-CD20s, which are extremely profitable. Their trend has been roughly flat, perhaps slightly decreasing. Then there’s TECFIDERA, which faces generic competition within the US. Naturally, we hold legal protection until early 2025, but as you’re aware, that product carries high margins; therefore, if you compare the growth path of those products against contract manufacturing — and we’ll keep being aggressive about chasing contract manufacturing chances whenever we can use them to fill capacity we’d otherwise leave empty — you’d anticipate that pressure on the gross margin percentage will persist. That’s something we will manage. We are seeing — we did record $34 million in idle capacity charges for the quarter. We hope that will diminish over time as LEQEMBI scales up and we can fully utilize our Solothurn facility. So that could serve as a potential offset. However, we don’t foresee substantial increases in our gross margin percentage, and that’s something we’ll have to manage. This is partly why we’ve placed such a sharp emphasis on operating expenses and rolled out such a significant cost reduction program.
Chuck Triano
executiveExcellent. Appreciate it, Mike. Can we take the next one, please?
Brian Skorney
analystMorning, everybody. Thanks for the opportunity to ask. I really only have a single item. Your company played a part in the creation of both LEQEMBI and ADUHELM. One thing that stands out is what looks like a differing profile between these two medicines when it comes to ARIA rates, yet those gaps appear even though the platform is quite similar. So I suppose plenty of speculation exists, and perhaps substantial uncertainty remains, regarding the mechanism underneath. Is there anything you could share about how you think through how much of this might be driven by subspecies targets? How much might simply come down to PK? It does seem as though the subcu remarks suggest that at least a portion could be tied to Cmax. But what is your current view on the mechanism behind ARIA?
Priya Singhal
executiveYes. Thanks, Brian. Broadly speaking, the mechanism of ARIA isn't something we completely grasp, yet for LEQEMBI the data have been reproduced when it comes to a low incidence of ARIA, in the sense that if you set it against certain other anti-amyloid — anti-beta amyloid antibodies, it comes out markedly lower, and that has been replicated twice. As an illustration, in the Clarity AD study, our ARIA-E rate was roughly 12.6%. With Donanemab, however, an ARIA-E rate of 24% shows up, and the proportions with ARIA-H look quite similar. So I think the population recruited also matters. As Chris said, these populations differed somewhat, with MCI sitting in the early population, since we genuinely believe treatment needs to start earlier. That may be contributing. Still, on the whole, it's quite difficult to pin down precisely what might be causing that difference. What I believe can be stated is that the incidence is observed to be markedly different. Hence, in my view, the benefit-risk differs as well. And that, I think, is the thing physicians ought to consider. Add to that the work behind — we have a very clear window of susceptibility with ARIA and LEQEMBI that we observe; we know it is essentially limited to the first six months. No titration occurs, so the rates we see are what we get. After that it drops away entirely, and recurrence is extremely uncommon. This is helpful to us, since we can assist physicians in truly getting on board, remaining on the monitoring plan, and that is genuinely where Eisai's focus lies with their understanding ARIA program. So all in all, we need to weigh the benefit-risk. So we have the general AD patient group that wasn’t selected through tau substratification for LEQEMBI, and the data extend all the way through tau PET, since, as everyone knows, amyloid tends to advance into neurofibrillary tangles. That makes it very useful to recognize that LEQEMBI has wide applicability, and that a risk profile also exists within the broader patient population. With — as you’re aware, there is a box warning for ApoE4 patients, who experience ARIA at a higher rate. And again, this is truly what we observe across the various molecules.
Christopher Viehbacher
executivePriya and I were talking about something — Robin Kramer and Priya, that is, over the weekend, after that really fascinating paper came out regarding everything that went on at AAIC and the differences reported. What really hit me is just how complicated all of this is, and how much analysis and understanding is genuinely required. But one point that stood out to me was this: safety differs not only across the overall population — we're also seeing that same pattern within each subgroup.
Priya Singhal
executiveRight. Each and every subgroup.
Christopher Viehbacher
executiveWhen you look at the ApoE category, there's a distinction between heterozygous and homozygous. And were these medications alike, you wouldn't anticipate a difference that dramatic. In certain subgroups, we're talking about a safety ratio that can reach 3:1. That's the reason I believe we will devote a great deal more effort to figuring out what is actually happening here. And that's what I mentioned at the beginning. We are truly only at the beginning of this. There remains a tremendous amount we don't yet understand, yet this will spark a huge amount of research, and we're going to begin examining this and grasping all those various subtleties that exist. But I believe these distinctions will prove rather significant. As Priya stated, that question isn't settled yet, though we have a great many indications of what is actually happening here. And that's why, as a company, as Biogen, we don't view the launch of LEQEMBI as the conclusion of our dedication to Alzheimer's. As Priya noted, we have additional Alzheimer's programs, and we will keep conducting research, since it truly is our ambition to be, together with our partners, Eisai, the clear leader in what we believe will be a remarkably substantial market.
Chuck Triano
executiveGreat. Thank you for the insights. Next question, please.
Chris Schott
analystThanks a lot for taking the question. I wanted to say I appreciate all the detail provided on this call. But let me return to LEQEMBI and the trajectory from this point. I realize you've described this as something of a step-by-step progression. Still, given the initial reactions you've gotten from the market since the launch, is there anything more you can share? Is it moving more quickly or more slowly than you'd expected? And perhaps alongside that, what would you say are the main favorable or unfavorable developments in the rollout so far, as we attempt to get a better sense of how to evaluate the coming quarters and years? Many thanks.
Christopher Viehbacher
executiveWell, regarding what one expects, it's somewhat difficult, as I mentioned, since this marks just the second occasion during my career when I've witnessed an entirely new therapeutic area begin to emerge. So, when you consider Alzheimer's patients and their visits to neurologists, apart from cognitive testing and, as I noted, possibly writing a prescription for an anti-cholinergic such as donepezil, there hasn't been a great deal available to offer. And at present we do have a therapy. This will disrupt numerous workflows inside neurology practices. It's tremendously thrilling; yet honestly, how quickly it's adopted hinges on the readiness of the sites. That varies across the country. Some sites exist. Clearly, they took part in clinical trials. A number of them serve differing patient groups, and we observe that certain sites are fairly far along and prepared to begin. Other sites have taken more of a wait-and-see stance, though I believe all of them are building momentum. One effort on our part has been — really attempting to determine which sites are genuinely prepared and then directing our people toward those locations, followed by a second-tier strategy for locations that aren't yet prepared, assisting them; so — so everything really rests on how far along those sites are, how prepared they happen to be, and that will truly determine adoption. That's the reason we must aim our resources accordingly and carefully evaluate site activation, so to speak. But up to this point, we're receiving plenty of encouraging responses. Doctors are fielding many questions from patients. I believe they'll need to determine precisely which patient is appropriate for this, and that's where extensive education becomes necessary; we have online offerings and other initiatives designed to help teach physicians. There's a considerable amount. I mean, you're merely discussing what we've already covered regarding these protofibrils, regarding the various patient groups — all of that will draw in the entire neurology community here; but up to this point, everything is — from our standpoint, the launch is proceeding according to plan.
Chuck Triano
executiveThanks, Chris. And if we can just take our last question, operator.
Paul Matteis
analystHi there. I appreciate you answering my question. I just wanted to touch on zuranolone for a moment. Compared with earlier calls, I've found it pretty striking how little this came up during the prepared remarks today. So is that just me reading too much into it? My assumption is you're preparing for a possible new antidepressant approval. And Chris, you referred to this at one stage as our most undervalued asset. So do you feel as enthusiastic about this drug as you did previously? And suppose the MDD approval didn't come through, and only PPD was granted — what would Biogen's approach be to capture that opportunity? Thank you.
Christopher Viehbacher
executiveWell, we're currently in late-stage review. So I'd say it's fairly standard that we'd rather not interfere with that process. And clearly we don't want to make any statement that could influence the FDA. I should admit that I'm a bit superstitious myself. And honestly, I'd prefer to wait for the FDA's decision, and after that we'd gladly discuss it at length. But the opportunity out there is enormous, Paul.
Chuck Triano
executiveOkay. Thanks, Chris, and thanks to everybody today for joining.
Operator
operatorThat wraps up the conference call for today. We appreciate you joining us. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.